within Pharmacolibrary.Drugs.ATC.A;

model A02BC06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 11.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,
    adminCount     = 1,
    Vd             = 0.040299999999999996,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016,
    Tlag           = 3600
  );

  annotation(Documentation(
    info ="<html><body><p>Dexlansoprazole is a proton pump inhibitor (PPI) used for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-related disorders. It is the R-enantiomer of lansoprazole and is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration of dexlansoprazole delayed-release capsules.</p><h4>References</h4><ol><li><p>Parekh, PJ, et al., &amp; Johnson, DA (2014). Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium). <i>Expert opinion on pharmacotherapy</i> 15(9) 1215–1222. DOI:<a href=&quot;https://doi.org/10.1517/14656566.2014.911841&quot;>10.1517/14656566.2014.911841</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24749891/&quot;>https://pubmed.ncbi.nlm.nih.gov/24749891</a></p></li><li><p>Han, S, et al., &amp; Bae, KS (2023). Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. <i>Gut and liver</i> 17(1) 92–99. DOI:<a href=&quot;https://doi.org/10.5009/gnl220050&quot;>10.5009/gnl220050</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36317518/&quot;>https://pubmed.ncbi.nlm.nih.gov/36317518</a></p></li><li><p>Vakily, M, et al., &amp; Mulford, D (2009). Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. <i>Current medical research and opinion</i> 25(3) 627–638. DOI:<a href=&quot;https://doi.org/10.1185/03007990802693883&quot;>10.1185/03007990802693883</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19232037/&quot;>https://pubmed.ncbi.nlm.nih.gov/19232037</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A02BC06;
